Key facts
- Trinomab(Zhuhai)’s last known valuation is $533.7M (Jun 2025).
- It has raised $221.2M; the latest was IPO in Jul 2025.
- Notable investors include GL Ventures, CICC Capital, Shenzhen Guozhong Venture Capital Management, Guolian Investment, Shenzhen Yifeng Investment Management Enterprise — 27 tracked in total.
- Status: In IPO Registration.
Investors
27+- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Trinomab(Zhuhai)
- ·The full record, as it builds
Funding rounds
No funding rounds for Trinomab(Zhuhai) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trinomab(Zhuhai)
Developer of antibody biopharmaceuticals designed for related medical research services. The company's research revolves around antibodies that can be used to treat viral infections and surgery-caused infections, enabling healthcare providers to prescribe better treatments to their patients.
- Sector
- Healthcare
- HQ
- Zhuhai, China
- Founded
- 2015
- Employees
- 767
- Website
- trinomab.com/
- Ownership
- In IPO Registration
Trinomab(Zhuhai) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trinomab(Zhuhai) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trinomab(Zhuhai) in its N-PORT filings yet. We sweep new filings monthly.